{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:11:09Z","timestamp":1790086269321,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.atherosclerosis.2016.08.043","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T17:12:07Z","timestamp":1473441127000},"page":"254-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["A phase III randomized trial evaluating alirocumab 300\u00a0mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I"],"prefix":"10.1016","volume":"254","author":[{"given":"Eli M.","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4034-2243","authenticated-orcid":false,"given":"Gisle","family":"Langslet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab vs. ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib3","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin vs. other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib6","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib8","doi-asserted-by":"crossref","first-page":"A1375","DOI":"10.1016\/S0735-1097(14)61375-9","volume":"63","author":"Rey","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40256-015-0119-2","article-title":"Impact of ezetimibe alone or in addition to a statin on plasma PCSK9 concentrations in patients with type 2 Diabetes and hypercholesterolemia: a pilot study","volume":"15","author":"Miyoshi","year":"2015","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib11","series-title":"Dynamics between the Monoclonal Antibody SAR236553\/REGN727, Proprotein Convertase Subtilisin\/kexin Type 9 (PCSK9) and Low-density Lipoprotein Cholesterol (LDL-C) Levels","author":"McKenney","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib12","series-title":"Alirocumab in Patients with Hypercholesterolemia Not on Statin Therapy: the ODYSSEY CHOICE II Study","author":"Stroes","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the national cholesterol education Program adult treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/clc.22327","article-title":"Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies","volume":"37","author":"Robinson","year":"2014","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2261-14-121","article-title":"Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials","volume":"14","author":"Colhoun","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40261-013-0129-2","article-title":"Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin\/kexin type 9","volume":"33","author":"Guo","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.atherosclerosis.2016.08.043_bib20","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016313119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016313119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T03:32:33Z","timestamp":1668569553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016313119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":20,"alternative-id":["S0021915016313119"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.043","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III randomized trial evaluating alirocumab 300\u00a0mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}